ArticleJournal of controlled release : official journal of the Controlled Release Society2013
Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 101 citations in OpenAlex.
- Identification of ANC-3 as a Novel Therapeutic Candidate for Anaplastic Thyroid Cancer Through Drug Screening and Multi-Platform Validation.International journal of molecular sciences · 2026Article
- Toward Translation of Cowpea Mosaic Virus Intratumoral Immunotherapy With a Scalable Production Process.Plant biotechnology journal · 2025Article
- A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine.Nature communications · 2025Article
- Risk factors for ICU-acquired weakness in sepsis patients: A retrospective study of 264 patients.Heliyon · 2024Article
- Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus.Materials advances · 2024Article
- A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection.Journal of materials chemistry. B · 2023Article
- Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics.Bioactive materials · 2023Article
- Targeting of Tomato Bushy Stunt Virus with a Genetically Fused C-End Rule Peptide.Nanomaterials (Basel, Switzerland) · 2023Article
- Nanomedicine approaches to reduce cytokine storms in severe infections.Drug discovery today · 2022Review
- Genetically Engineered Viral Vectors and Organic-Based Non-Viral Nanocarriers for Drug Delivery Applications.Advanced healthcare materials · 2022Review
- Protein-Based Encapsulation Strategies: Toward Micro- and Nanoscale Carriers with Increased Functionality.Small science · 2022Article
- Transport of Molecular Cargo by Interaction with Virus-Like Particle RNA.Angewandte Chemie (International ed. in English) · 2022Article
- Bacteriophage PRD1 as a nanoscaffold for drug loading.Nanoscale · 2021Article
- Isolation of Cowpea Mosaic Virus-Binding Peptides.Biomacromolecules · 2021Article
- Frontiers in Bioengineering and Biotechnology: Plant Nanoparticles for Anti-Cancer Therapy.Vaccines · 2021Review
- Recent progress in targeted delivery vectors based on biomimetic nanoparticles.Signal transduction and targeted therapy · 2021Review
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
- A smart viral vector for targeted delivery of hydrophobic drugs.Scientific reports · 2021Article
- Remission-Stage Ovarian Cancer Cell Vaccine with Cowpea Mosaic Virus Adjuvant Prevents Tumor Growth.Cancers · 2021Article
- Plant Virus Nanoparticles for Anti-cancer Therapy.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
This work is focused on the development of a plant virus-based carrier system for cargo delivery, specifically 30nm-sized cowpea mosaic virus (CPMV). Whereas previous reports described the engineering of CPMV through genetic or chemical modification, we report a non-covalent infusion technique that facilitates efficient cargo loading. Infusion and retention of 130-155 fluorescent dye molecules per CPMV using DAPI (4',6-diamidino-2-phenylindole dihydrochloride), propidium iodide (3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide), and acridine orange (3,6-bis(dimethylamino)acridinium chloride), as well as 140 copies of therapeutic payload proflavine (PF, acridine-3,6-diamine hydrochloride), is reported. Loading is achieved through interaction of the cargo with the CPMV's encapsidated RNA molecules. The loading mechanism is specific; empty RNA-free eCPMV nanoparticles could not be loaded. Cargo-infused CPMV nanoparticles remain chemically active, and surface lysine residues were covalent modified with dyes leading to the development of dual-functional CPMV carrier systems. We demonstrate cargo-delivery to a panel of cancer cells (cervical, breast, and colon): CPMV nanoparticles enter cells via the surface marker vimentin, the nanoparticles target the endolysosome, where the carrier is degraded and the cargo is released allowing imaging and/or cell killing. In conclusion, we demonstrate cargo-infusion and delivery to cells; the methods discussed provide a useful means for functionalization of CPMV toward its application as drug and/or contrast agent delivery vehicle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.